top of page

PROMO

OCTOBER 20th 2026

Check Out Our Promotions Page To View All Current Promo's

 FREE 3ml BACSTERIOSTAIC WATER WITH EVERY ORDER! (T+c)

Dont Miss Out! | Save Up-to 40% | Fire Sale | Ends Nov 31st

Peptide Identity Testing: What HPLC, LC-MS and a COA Actually Prove

2 days ago
6 min read

A certificate of analysis (COA) may report 99% HPLC purity, yet that number alone cannot establish that a vial contains the intended peptide, the labelled mass, or a sterile preparation. These are different analytical questions, and each requires evidence appropriate to the claim.

For Canadian laboratories evaluating research peptides, the most useful starting point is to separate four terms: identity, chromatographic purity, quantitative assay and microbiological quality. Newer peptide-specific guidance from the European Medicines Agency, effective June 2026, makes that distinction especially clear.

Peptide Identity, Purity and Content Are Different Measurements

Identity asks which molecular structure is present. Purity asks which detected components are present relative to one another under a defined analytical method. Assay measures the amount of the target substance. Sterility and endotoxin testing assess microbiological hazards that chemical chromatography does not rule out.

What a COA Result Actually Means

A COA is a report of specified test results for a particular sample or batch. Its evidentiary value depends on the test method, sample identification, acceptance criteria, laboratory traceability and availability of underlying data. A report that states 'purity 99%' without naming the method and detector is difficult to interpret.

For example, a reversed-phase HPLC chromatogram may show one dominant UV-absorbing peak. That does not establish that 99% of the total lyophilized vial mass is the desired peptide. Water, counterions, non-UV-active components and excipients may contribute to mass without appearing as equivalent chromatographic peaks.

How HPLC Measures Peptide Purity

High-performance liquid chromatography separates components according to their interactions with a stationary phase and mobile phase. Reversed-phase HPLC is widely used for synthetic peptide impurity profiling. UV detection then records absorbance as components leave the column.

An area-normalized purity result is generally calculated from the target peak area divided by the sum of integrated peak areas, multiplied by 100. This calculation assumes that the chosen peaks and detector responses are suitable for the intended interpretation.

Worked Example: Why 99% Peak Area Is Not 99 mg of Peptide

Suppose an illustrative chromatogram has a main-peak area of 990,000 and integrated impurity peak areas totalling 10,000. The area-normalized main-peak fraction is 990,000 / 1,000,000 × 100 = 99.0%. This is a hypothetical chromatographic example, not a measurement from a Kelden batch.

That percentage does not determine whether the sample contains 10 mg, 20 mg or 50 mg of target peptide. Absolute content requires a suitable quantitative assay with calibration and consideration of water, counterions and formulation components.

What LC-MS Adds to Peptide Identification

Liquid chromatography–mass spectrometry combines chromatographic separation with measurement of ion mass-to-charge ratio (m/z). Accurate mass can support molecular formula or peptide identity assignments, while tandem mass spectrometry (MS/MS) can provide fragment-ion evidence for sequence and structural features.

However, intact mass alone may not distinguish every positional isomer, amino-acid sequence isomer or stereoisomer. Different structures can share the same nominal or exact mass. Confirmatory approaches may include MS/MS, peptide mapping, amino-acid analysis, chiral methods or NMR, depending on the question.

The EMA's 2025 synthetic-peptide guideline, effective June 2026, recommends at least two orthogonal identification methods and requires the combination to be capable of unambiguously confirming peptide sequence. FDA ICH Q6A likewise cautions that identification based only on one chromatographic retention time is not sufficiently specific.

Mass Accuracy: A Worked Example

Consider a hypothetical target monoisotopic neutral mass of 1,000.0000 Da and an experimentally assigned mass of 1,000.0050 Da. The mass error is (1,000.0050 − 1,000.0000) / 1,000.0000 × 1,000,000 = +5 ppm. Whether that is acceptable depends on the instrument, calibration, ion assignment and method criteria. It does not by itself prove sequence identity.

Why Two Orthogonal Methods Are Stronger

Orthogonal methods probe different chemical properties. Chromatographic retention, intact mass, fragmentation patterns, amino-acid composition and stereochemistry are not interchangeable measurements. Agreement between independent techniques reduces the risk of misidentifying a co-eluting or structurally similar impurity.

A 2026 peer-reviewed review of peptide quality assessment summarizes the roles of mass spectrometry, peptide mapping, amino-acid analysis and NMR. It also reports industry use of RP-HPLC for peptide-related impurities and complementary size-exclusion methods for aggregates.

Impurities: What Laboratories Need to Look For

Synthetic peptide manufacture can introduce deletion sequences, truncated sequences, insertion variants, oxidation products, deamidation products, epimers and residual process-related substances. Storage can generate additional degradation products.

A 2025 experimental study of peptide pools used UHPLC and high-resolution mass spectrometry to investigate synthesis by-products, storage-related degradation and analytical artifacts. Its findings illustrate why the impurity profile can contain more information than a single summary purity number.

Some impurities co-elute with the target peptide. Others respond differently to a UV detector. Method suitability, resolution, peak integration and orthogonal confirmation therefore matter as much as the headline percentage.

Purity Is Not Sterility

HPLC and LC-MS are chemical analytical techniques. They do not establish that a material is sterile or free of bacterial endotoxins. Microbiological quality requires separately validated methods, suitable sampling and clearly identified acceptance criteria.

Likewise, a passing sterility test does not identify a peptide sequence or prove its labelled content. A complete quality evaluation answers these questions separately.

How to Read a Peptide COA

Before interpreting a COA, verify the peptide name and sequence, batch or sample identifier, laboratory and report date, stated analytical method, observed mass or identity evidence, chromatographic integration, purity calculation, assay or content result where relevant, and whether sterility or endotoxin results are actually included.

A chromatogram and a mass spectrum can strengthen the report, but their interpretation still depends on calibration, specificity and suitable controls. A COA should not be treated as a universal guarantee beyond the tests actually performed.

What Does the Evidence Show in Humans, Animals and In Vitro?

This article addresses analytical measurement, not a therapeutic effect. Its primary evidence consists of instrumental laboratory experiments, analytical method research, pharmaceutical quality guidance and published method assessments. Human clinical trials and animal efficacy studies are not needed to establish the basic distinction between chemical identity, purity, assay and sterility; they would answer different questions about biological effects.

Peptide Testing in Canada

Canadian researchers, including laboratories in Vancouver and British Columbia, can use the same fundamental analytical distinctions when reviewing domestic or international peptide documentation. International guidelines provide useful scientific benchmarks, but a specific research COA should be judged against its actual methods and the purpose for which the material is being evaluated.

Kelden Peptide Sciences Canada provides batch-related documentation through its Lab Reports and Sterility Reports sections. Review the reported tests individually rather than assuming that one result establishes every quality attribute.

Frequently Asked Questions

Does 99% HPLC purity mean a vial contains 99% peptide by weight?

No. HPLC area percentage generally reflects the proportion of integrated detector response under the stated method, not the fraction of total vial mass that is active peptide.

Can LC-MS confirm the exact peptide sequence?

LC-MS can strongly support identity, especially with MS/MS fragmentation and appropriate standards. Intact mass alone cannot always distinguish structural isomers or stereoisomers.

Can UV-Vis confirm a peptide's identity?

UV-Vis measures absorbance. It can be useful for concentration measurements with validated calibration and suitable specificity, but a UV spectrum alone usually cannot unambiguously confirm a peptide sequence.

What is the difference between HPLC purity and peptide assay?

Purity describes the relative impurity profile under the method. Assay measures the quantity of the target peptide, usually against a reference standard.

Does an LC-MS result prove sterility?

No. Sterility and bacterial endotoxin require separate microbiological testing.

What does orthogonal testing mean?

It means using methods based on sufficiently different measurement principles to strengthen confidence in a result, such as chromatography combined with mass spectrometry and sequence-specific evidence.

Can two peptides have the same mass?

Yes. Sequence isomers and stereoisomers may have identical molecular masses. Additional structural testing may be necessary.

Conclusion

A scientifically useful peptide COA does more than display a high purity percentage. It connects a specific sample to methods that can answer distinct questions about identity, impurity profile, content and microbiological quality. HPLC and LC-MS are complementary tools, but neither one alone establishes every property of a research material.

Scientific References

Related Kelden Resources

 
 

Recent Posts

See All
bottom of page